SCR-A006

N/A

Report date: 2025/07/09 16:21:37

Base Information

Drug NameSCR-A006
Drug Alias NameSCR-A006
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-Hepatocyte growth factor receptorDNA topoisomerase I inhibitors
TargetsEpidermal growth factor receptor erbB1Hepatocyte growth factor receptorDNA topoisomerase I
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSimcere Pharmaceutical Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSimcere Pharmaceutical Group Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A